A 42-year-old user shared a 4-month update on their hair regrowth using a "nuclear stack" including oral and topical minoxidil, dutasteride, RU58841, micro-needling, keto shampoo, saw palmetto, biotin, multivitamins, scalp massages, and inversion table. They reported significant progress with minimal side effects and plan to continue the routine.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
A user shared their successful hair regrowth journey using oral minoxidil, dutasteride, and eucapil, with additional benefits from MTF hormone replacement therapy. They advised consulting specialists and considering individual responses to treatments.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.
The user experienced subtle hair growth improvements using finasteride, dutasteride, and minoxidil over nearly three years, with notable progress at the temples. The front hairline shows quicker regrowth cycles, but the vertex and crown remain unchanged.
A user shared their progress with hair loss treatment using Dutasteride Mesotherapy but mentioned they ruined their progress. Another user commented that Minoxidil caused shedding, which should regrow in three months.
Significant hair regrowth was achieved using 1 mg Finasteride, 5% Minoxidil, and dermarolling, with a switch from a 0.5 mm to a 1 mm roller after two months. The user is happy with the results but is still considering a hair transplant for more density.
The user compared microneedling with a stamp versus a pen, finding the Dr. Pen more effective and easier to use than the Bioneedle stamp. They also mentioned using oral minoxidil for hair loss treatment.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
The user has been using oral Minoxidil, Finasteride, and dermarolling for two months to address hair loss and is considering continuing the treatment until December before possibly switching to Dutasteride. They are hesitant about getting a hair transplant and are exploring other options like SMP, while receiving encouragement and advice from others to continue the current regimen for a longer period to see more results.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
After 2 months of using Minoxidil and finasteride, OP noticed fuller hair, confirmed by their wife's observation. OP is pleased with the progress, though the change isn't drastic.
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The user has been using Morr-F Aqua 5% (minoxidil) once daily for over three months to address male pattern baldness and is seeking feedback on their progress. They are unsure if the current dosage is sufficient and whether the aqueous base is effective compared to other versions.
The post is about a user sharing progress pictures of their hair loss, comparing the appearance of their crown before and after using finasteride for 1 week to 4 months. The user also mentions using minoxidil and starting microneedling.
OP experienced significant hair regrowth after recovering from iron deficiency anemia and starting minoxidil. They suspect anemia contributed more to their hair loss than androgenetic alopecia (AGA).
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
Use finasteride or dutasteride with minoxidil for at least a year to improve hair density before considering a hair transplant. A transplant might be needed if medications don't provide sufficient regrowth.
The user shared progress after two months of using finasteride, serioxyl, and NOOANCE casque Pro for alopecia. They are documenting their hair loss treatment journey.
A user shared their 10-month progress using Finasteride, Minoxidil, and a Derma Roller for hair loss, showing significant improvement in hair coverage and hairline. Some commenters questioned the before and after photos, while others congratulated the user on the successful results.
The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.
The user uses a 1.5mm derma stamp weekly for hair loss and applies minoxidil afterward, feeling a slight burn but no bleeding. They question if bleeding, seen in others using a derma pen, indicates proper technique.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.